Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program 'Health Development' in patients with heart failure

MLA

M. V. Zhuravleva, et al. “Cost-Effectiveness of Valsartan+sakubitril, Dapagliflosin and Empagliflosin for Prevention of Cardiovascular Death and Reducing Cardiovascular Mortality within the State Program ‘Health Development’ in Patients with Heart Failure.” Российский Кардиологический Журнал, vol. 28, no. 12, Dec. 2023. EBSCOhost, https://doi.org/10.15829/1560-4071-2023-5711.

APA

M. V. Zhuravleva, S. N. Tereshchenko, F. N. Paleev, Yu. V. Gagarina, & E. A. Shabalina. (2023). Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program “Health Development” in patients with heart failure. Российский Кардиологический Журнал, 28(12). https://doi.org/10.15829/1560-4071-2023-5711

Chicago

M. V. Zhuravleva, S. N. Tereshchenko, F. N. Paleev, Yu. V. Gagarina, and E. A. Shabalina. 2023. “Cost-Effectiveness of Valsartan+sakubitril, Dapagliflosin and Empagliflosin for Prevention of Cardiovascular Death and Reducing Cardiovascular Mortality within the State Program ‘Health Development’ in Patients with Heart Failure.” Российский Кардиологический Журнал 28 (12). doi:10.15829/1560-4071-2023-5711.